Soros Fund Management’s Neurocrine Biosciences NBIX Stock Holding History

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-239,823	Closed	-$26.5M	–	244
2025 Q1	$26.5M	Buy	239,823 +39,823	+20%	+$5.04M	0.4%	69
2024 Q4	$27.3M	Buy	200,000 +50,000	+33%	+$6.18M	0.41%	67
2024 Q3	$17.3M	Sell	150,000 -44,776	-23%	-$6.14M	0.25%	89
2024 Q2	$26.8M	Buy	194,776 +35,000	+22%	+$4.8M	0.48%	55
2024 Q1	$22M	Sell	159,776 -25,224	-14%	-$3.44M	0.37%	77
2023 Q4	$24.4M	Buy	185,000 +130,000	+236%	+$15M	0.32%	80
2023 Q3	$6.19M	Buy	+55,000	New	+$5.79M	0.09%	146
2017 Q4	–	Sell	-11,300	Closed	-$692K	–	252
2017 Q3	$692K	Buy	11,300 +6,400	+131%	+$338K	0.02%	146
2017 Q2	$225K	Buy	+4,900	New	+$238K	﹤0.01%	190
2016 Q4	–	Sell	-11,322	Closed	-$573K	–	266
2016 Q3	$573K	Buy	+11,322	New	+$564K	0.01%	159
2016 Q2	–	Sell	-9,400	Closed	-$372K	–	220
2016 Q1	$372K	Buy	+9,400	New	+$373K	0.01%	183
2013 Q3	–	Sell	-200,000	Closed	-$2.68M	–	256
2013 Q2	$2.68M	Buy	+200,000	New	+$2.46M	0.03%	173